From Bench to Clinic: A Nitroreductase Rv3368c-Responsive Cyanine-Based Probe for the Specific Detection of Live Mycobacterium tuberculosis .
Xiaoqiao HongPengfei GengNa TianXueyuan LiMengqiu GaoLihui NieZhaogang SunGang LiuPublished in: Analytical chemistry (2024)
Tuberculosis (TB), characterized by high mortality and low diagnosis, is caused by a single pathogen, Mycobacterium tuberculosis ( Mtb ). Imaging tools that can be used to track Mtb without pre-labeling and to diagnose live Mtb in clinical samples can shorten the gap between bench and clinic, fuel the development of novel anti-TB drugs, strengthen TB prevention, and improve patient treatment. In this study, we report an unprecedented novel nitroreductase-responsive cyanine-based fluorescent probe ( Cy3-NO 2 -tre ) that rapidly and specifically labels Mtb and detects it in clinical samples. Cy3-NO 2 -tre generated fluorescence after activation by a specific nitroreductase, Rv3368c, which is conserved in the Mycobacteriaceae . Cy3-NO 2 -tre effectively imaged mycobacteria within infected host cells, tracked the infection process, and visualized Mycobacterium smegmatis being endocytosed by macrophages. Cy3-NO 2 -tre also detected Mtb in the sputum of patients with TB and exhibited excellent photostability. Furthermore, the Cy3-NO 2 -tre /auramine O percentage change within 7 ± 2 days post drug treatment in the sputum of inpatients was closely correlated with the reexamination results of the chest computed tomography, strongly demonstrating the clinical application of Cy3-NO 2 -tre as a prognostic indicator in monitoring the therapeutic efficacy of anti-TB drugs in the early patient care stage.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- fluorescent probe
- computed tomography
- living cells
- primary care
- induced apoptosis
- magnetic resonance imaging
- type diabetes
- high resolution
- cystic fibrosis
- risk factors
- transcription factor
- drug delivery
- single molecule
- mass spectrometry
- emergency department
- coronary artery disease
- signaling pathway
- replacement therapy
- cell cycle arrest
- adverse drug
- combination therapy
- drug induced